JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
© 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd..
BACKGROUND: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis.
METHODS: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation.
RESULTS: MPN patients had a higher observed richness (median, 245 [range, 49-659]) compared with HCs (191.5 [range, 111-300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation.
CONCLUSION: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
European journal of haematology - 112(2024), 5 vom: 16. Apr., Seite 776-787 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eickhardt-Dalbøge, Christina Schjellerup [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Calreticulin |
|---|
| Anmerkungen: |
Date Completed 04.04.2024 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.14169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367173336 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367173336 | ||
| 003 | DE-627 | ||
| 005 | 20240404234614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.14169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM367173336 | ||
| 035 | |a (NLM)38226781 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eickhardt-Dalbøge, Christina Schjellerup |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis | ||
| 520 | |a METHODS: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation | ||
| 520 | |a RESULTS: MPN patients had a higher observed richness (median, 245 [range, 49-659]) compared with HCs (191.5 [range, 111-300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation | ||
| 520 | |a CONCLUSION: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a essential thrombocythemia | |
| 650 | 4 | |a gut microbiota | |
| 650 | 4 | |a myeloproliferative neoplasms | |
| 650 | 4 | |a polycythemia vera | |
| 650 | 4 | |a primary myelofibrosis | |
| 650 | 7 | |a Calreticulin |2 NLM | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Nielsen, Henrik V |e verfasserin |4 aut | |
| 700 | 1 | |a Fuursted, Kurt |e verfasserin |4 aut | |
| 700 | 1 | |a Stensvold, Christen Rune |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Lee O' Brien |e verfasserin |4 aut | |
| 700 | 1 | |a Lilje, Berit |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Morten Kranker |e verfasserin |4 aut | |
| 700 | 1 | |a Kjær, Lasse |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Sarah Friis |e verfasserin |4 aut | |
| 700 | 1 | |a Knudsen, Trine Alma |e verfasserin |4 aut | |
| 700 | 1 | |a Skov, Vibe |e verfasserin |4 aut | |
| 700 | 1 | |a Sørensen, Anders Lindholm |e verfasserin |4 aut | |
| 700 | 1 | |a Ellervik, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Olsen, Lars Rønn |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Jens Jørgen Elmer |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Xiaohui Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Hasselbalch, Hans Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Ingham, Anna Cäcilia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 112(2024), 5 vom: 16. Apr., Seite 776-787 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2024 |g number:5 |g day:16 |g month:04 |g pages:776-787 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.14169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2024 |e 5 |b 16 |c 04 |h 776-787 | ||